AstraZeneca Plc (NASDAQ:AZN) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as well as safety and tolerability in participants with resistant hypertension. • AZN is approaching key resistance levels. Find out why here.The company released topline data in October.The trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour ...